間充質(zhì)干細(xì)胞（MSCs）具有多種分化能力，可以直接遷移到損傷組織中并分化為肺泡上皮細(xì)胞，還可以分泌并釋放多種細(xì)胞因子和外泌體，調(diào)節(jié)炎癥和免疫反應(yīng)。特發(fā)性肺纖維化（IPF）是與年齡相關(guān)、發(fā)病機(jī)制尚不明確的慢性進(jìn)行性肺部疾病，臨床上使用的吡非尼酮和尼達(dá)尼布僅能緩解癥狀。MSCs在治療IPF方面具有廣闊的應(yīng)用前景，就目前關(guān)于MSCs治療特發(fā)性肺纖維化的藥理機(jī)制以及該療法所存在的局限性進(jìn)行綜述和探討。

Mesenchymal stem cells (MSCs) have a variety of differentiation abilities, which can migrate directly to injured tissues and differentiate into alveolar epithelial cells. In addition, MSCs can secrete and release a variety of cytokines and exosomes to regulate inflammation and immune responses. Idiopathic pulmonary fibrosis (IPF) is an age-related chronic progressive disease with an unclear pathogenesis. The probable pathogenesis of IPF is the recurrent injury of the genetically susceptible alveolar epithelium followed by an abnormal repair response of excessive collagen deposition. The clinical use of Pirfenidone and Nintedanib can only alleviate the disease status of IPF patients. MSCs has broad application prospects in the treatment of idiopathic pulmonary fibrosis. To discuss the pharmacological mechanism of MSCs in the treatment of idiopathic pulmonary fibrosis and the limitations of this therapy.

中央引導(dǎo)地方科技發(fā)展專項（21ZYJDSY00120）